Group 1 - The company plans to repurchase shares through centralized bidding, with a repurchase amount between 40 million and 50 million yuan, and a maximum repurchase price of 25.77 yuan per share, which is 50.88% higher than the current price of 17.08 yuan [1] - The repurchase is expected to stabilize the stock price and can be used for employee stock ownership plans or equity incentive plans [1] - The company is involved in the research, production, and sales of high-value pharmaceutical excipients and in vitro diagnostic services, with its main business revenue composition including PVP other (39.57%), PVPK30 powder (28.35%), and early cancer diagnosis services (3.08%) [1] Group 2 - As of December 10, the number of shareholders is 18,900, a decrease of 5.03%, while the average circulating shares per person increased by 5.30% to 23,825 shares [2] - For the period from January to September 2025, the company reported a revenue of 951 million yuan, a year-on-year decrease of 14.36%, and a net profit attributable to the parent company of 201 million yuan, down 35.39% year-on-year [2] - The company has distributed a total of 900 million yuan in dividends since its A-share listing, with 607 million yuan distributed in the last three years [3]

北京商报讯（记者 丁宁）1月8日晚间，新开源（300109）发布公告称，基于对公司未来发展的信心和 对公司价值的认可，为增强投资者对公司的投资信心，维护广大股东利益，公司拟使用自有资金以集中 竞价交易方式回购部分公司股份，用于注销并减少注册资本。回购股份的资金总额不低于4000万元（含 本数）且不超过5000万元（含本数）。 ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

每经头条（nbdtoutiao）——培训5天就考证！滑雪教练速成班乱象调查：零基础也可报名，学时还 能"注水" 每经AI快讯，新开源1月8日晚间发布公告称，公司第五届第二十一次董事会会议于2026年1月7日在公 司三楼会议室以现场加通讯的表决方式召开。会议审议了《关于以集中竞价交易方式回购公司股份方案 的议案》等文件。 （记者 曾健辉） ...

格隆汇1月8日丨新开源(300109.SZ)公布，公司本次回购的公司股份将全部用于注销并减少注册资本。 回购股份的资金总额不低于人民币4,000万元（含本数）且不超过人民币5,000万元（含本数），具体以 回购期限届满时实际使用的资金总额为准。回购价格上限为25.77元/股。 ...

新开源（300109）(300109.SZ)公告，公司拟回购公司股份用于注销并减少注册资本。回购股份的资金 总额不低于4000万元(含本数)且不超过5000万元(含本数)。回购价格上限为25.77元/股。回购股份的期限 自公司股东大会审议通过本次回购方案之日起6个月内。 ...

人民财讯1月8日电，新开源（300109）1月8日公告，公司拟以4000万元—5000万元回购股份，将用于注 销并减少注册资本，回购价格上限为25.77元/股。 ...

智通财经APP讯，新开源(300109.SZ)公告，公司拟回购公司股份用于注销并减少注册资本。回购股份的 资金总额不低于4000万元(含本数)且不超过5000万元(含本数)。回购价格上限为25.77元/股。回购股份的 期限自公司股东大会审议通过本次回购方案之日起6个月内。 ...

证券代码：300109 证券简称：新开源 公告编号：2026-003 博爱新开源医疗科技集团股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： （一）本次回购基本情况 1、回购股份的种类：人民币普通股（A 股）股票。 2、回购股份的用途：本次回购的公司股份将全部用于注销并减少注册资本。 3、回购股份的价格：回购价格上限为 25.77 元/股，不高于董事会审议通过 回购股份决议前 30 个交易日公司股票交易均价的 150%。 4、回购股份的资金总额：不低于人民币 4,000 万元（含本数）且不超过人 民币 5,000 万元（含本数），具体以回购期限届满时实际使用的资金总额为准。 5、回购股份的资金来源：公司自有资金。 公司于 2025 年 11 月 25 日在在巨潮资讯网（www.cninfo.com.cn）披露了《关 于部分董事、高级管理人员股份减持计划的预披露公告》（公告编号：2025-040）， 公司董事、高级管理人员于江涛先生计划在前述公告披露之日起十五个交易日后 的 3 个月内（2025 年 12 ...

证券代码：300109 证券简称：新开源 公告编号：2026-004 博爱新开源医疗科技集团股份有限公司 一、召开会议的基本情况 1、会议届次：2026年第二次临时股东大会 2、召集人：公司董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议召开时间： 现场会议时间：2026年1月27日（星期二）下午14:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2026 年1月27日9:15-9:25,9:30-11:30,13:00-15:00；通过深圳证券交易所互联网系统投 票的具体时间为2026年1月27日9:15至15:00的任意时间。 5、会议召开方式：现场表决与网络投票相结合 关于召开2026年第二次临时股东大会的通知 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《公司章程》有关规定，经博爱新开源医 疗科技集团股份有限公 ...